Alkermes (ALKS) Cash from Operations Growth (5y) (2015 - 2026)
Alkermes (ALKS) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.71% |
| Dec 31, 2025 | 20.36% |
| Sep 30, 2025 | 11.05% |
| Jun 30, 2025 | 104.64% |
| Mar 31, 2025 | 34.82% |
| Dec 31, 2024 | 35.25% |
| Sep 30, 2024 | 21.38% |
| Jun 30, 2024 | 52.69% |
| Mar 31, 2024 | -1.01% |
| Dec 31, 2023 | 12.12% |
| Sep 30, 2023 | 24.39% |
| Jun 30, 2023 | 46.35% |
| Mar 31, 2023 | 4.52% |
| Dec 31, 2022 | -50.69% |
| Sep 30, 2022 | -49.74% |
| Jun 30, 2022 | 36.57% |
| Mar 31, 2022 | 29.03% |
| Dec 31, 2021 | 32.63% |
| Sep 30, 2021 | 41.23% |
| Jun 30, 2021 | 25.75% |